Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

# AGENCY:

National Institutes of Health, HHS.

# ACTION:

Notice.

# SUMMARY:

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.

# FOR FURTHER INFORMATION CONTACT:

                        Licensing information may be obtained by emailing the licensing contact Malabika Ghosh, J.D., Ph.D.; 301-827-5414;                         *Malabika.Ghosh@nih.gov,*                         at the National Heart, Lung, and Blood, Office of Technology Transfer and Development, 31 Center Drive Room 4A25, MSC2479, Bethesda, MD 20892-2479. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.                    

# SUPPLEMENTARY INFORMATION:

Technology description follows.

## Analogues of N-Lactoyl-Phenylalanine, Methods of Synthesis, and Methods of Use

Available for licensing and commercial development are patent rights covering N-Lactoyl-Phenylalanine (Lac-Phe) analogues having appetite suppressant activity, which may be useful as therapeutics in the treatment of obesity and related secondary diseases. The patent rights also cover methods of synthesis of the N-Lactoyl-Phenylalanine (Lac-Phe) analogues are also disclosed, as well as methods of use and treatment of obesity and related secondary diseases with the Lac-Phe analogues.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

### Inventors

    - Alan T. Remaley, M.D., Ph.D. NHLBI
    - Anna Wolska, Ph.D. NHLBI
    - Amaury Lucien-Philip Dasseux

### Potential Commercial Applications

    - Therapeutics

○ obesity

○ obesity co-morbidities

### Development Stage

    - Preclinical (data from compound optimization and in vivo validation)

### Intellectual Property

    - NIH Reference No. E-160-2023-0, U.S. Provisional Patent Application 63/585,791 filed September 27, 2023, International Patent Application PCT/US2024/048617 filed September 26, 2024, entitled “N-Lactoyl-Phenylalanine (Lac-Phe) compound derivatives.”

      ( print page 95801)    
Dated: November 27, 2024.

Malabika J. Ghosh,

Technology Transfer and Patent Specialist, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

[FR Doc. 2024-28329 Filed 12-2-24; 8:45 am]

BILLING CODE 4140-01-P